ATC Group: A10AD05 Insulin aspart

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10AD05 in the ATC hierarchy

Level	Code	Title
`1`	A	Alimentary tract and metabolism
`2`	A10	Drugs used in diabetes
`3`	A10A	Insulins and analogues
`4`	A10AD	Insulins and analogues for injection, intermediate-acting combined with fast-acting
`5`	A10AD05	Insulin aspart

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
PAREN	Parenteral	40 [iU]

Active ingredients in A10AD05

Active Ingredient
Insulin aspart
The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.

Related product monographs

Document	Type	Information Source
NOVOMIX 50 Suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)
NOVOMIX 70 Suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)
TRUVELOG MIX 30 Suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)